Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
N/A
1(33.3%)
3Total
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06646198Phase 2Recruiting

TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension

Role: lead

NCT05882370Phase 2Recruiting

TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study

Role: lead

NCT05852132Not ApplicableNot Yet Recruiting

Clinical Study on Prognosis of Patients With Severe NPDR Undergoing Vitrectomy

Role: lead

All 3 trials loaded